Core Insights - CNX Resources Corporation (CNX) reported second-quarter 2025 operating earnings of 59 cents per share, exceeding the Zacks Consensus Estimate of 39 cents by 51.3% and increasing 63.9% from 36 cents in the same quarter last year [1][8] CNX's Revenues - The company reported revenues of $450 million, missing the Zacks Consensus Estimate of $457 million by 1.4%, but showing a 30.1% increase from $346 million in the prior-year quarter [2] Highlights of CNX's Q2 Release - The average selling price in the quarter was $2.68 per thousand cubic feet equivalent (Mcfe), up 3.9% from $2.58 a year ago - Total production cost was $1.67 per Mcfe, down 2.3% year over year - Total production volumes were 167.6 billion cubic feet equivalent (Bcfe), up 25.1% year over year - Interest expenses totaled $44 million, up 13.9% year over year [3][8] Share Repurchase and Debt Management - During the second quarter, CNX repurchased 3.7 million shares at an average price of $31.24 per share for a total cost of $114 million, representing approximately 40% of its outstanding shares over the past 19 quarters - CNX's adjusted net debt decreased by $69 million [4][8] Financial Update - As of June 30, 2025, CNX had cash and cash equivalents of $3.39 million, down from $17.2 million as of December 31, 2024 - Long-term debt increased to $2.29 billion from $1.84 billion as of December 31, 2024 - Cash from operating activities for the first six months of 2025 totaled $282.5 million compared to $191.8 million in the year-ago period, with free cash flow amounting to $188 million [5] Capital Expenditure - Capital expenditure for the first six months totaled $113.6 million, down from $151.9 million in the year-ago period [6] CNX's Guidance - CNX expects total capital expenditure for 2025 to be between $450 million and $500 million - The company anticipates 2025 production volume to be in the range of 615-620 Bcfe, an increase from the previous guidance of 605-620 Bcfe - Total free cash flow is expected to be $575 million [7][9]

Core Insights - Woodward, Inc. (WWD) is set to report its third-quarter fiscal 2025 results on July 28, with revenue expectations of $887.8 million, reflecting a 4.7% increase year-over-year, while earnings per share (EPS) are projected to decline by 0.6% to $1.62 [1][9] - The company has consistently exceeded earnings estimates in the past four quarters, with an average surprise of 15.6% [1][9] Revenue and Segment Performance - The Aerospace segment is anticipated to drive performance in the fiscal third quarter, supported by growth in the commercial aftermarket and increased defense activity [4] - The Industrial segment is experiencing strong demand for power generation and backup power for data centers, with a narrowed revenue decline projection of 7-9% for fiscal 2025 [5][6] - Revenue from the Aerospace segment is expected to rise by 10.3% to $571 million, while the Industrial segment is projected to decline by 7.8% to $304.4 million for the fiscal third quarter [6] Market Challenges - The on-highway natural gas truck market in China is facing volatility, with sales reported at $21 million in the last quarter and a full-year revenue expectation of only $40 million, down significantly from $175 million in fiscal 2024 [7][8] - Global macroeconomic weakness and rising costs are additional concerns impacting WWD's Industrial performance [7][9] Recent Developments - On July 21, 2025, WWD completed the acquisition of Safran's Electronics & Defense electromechanical actuation business, enhancing its capabilities in aircraft stabilization systems [10] - WWD was selected by Airbus to supply the electro-hydraulic Spoiler Actuation System for the A350 aircraft, which includes hardware delivery and long-term maintenance services [11] Earnings Prediction - The company's earnings model indicates a likely earnings beat, supported by a positive Earnings ESP of +4.29% and a Zacks Rank of 1 (Strong Buy) [12]

Core Insights - Investors are focused on the performance of the lead drug Cabometyx as Exelixis prepares to report its second-quarter 2025 results on July 28, with sales and earnings estimates at $527 million and 63 cents per share respectively [1][6] Group 1: Earnings Performance - Exelixis has consistently beaten earnings estimates in the past four quarters, with an average surprise of 48.6%, including a 47.62% beat in the last reported quarter [2] - The company's earnings ESP is +2.52%, with the consensus estimate at 63 cents per share and the most accurate estimate at 65 cents [12] Group 2: Revenue Drivers - Revenue generation comes from net product sales, license revenues, and collaboration and service revenues, with net product revenues likely increasing due to higher Cabometyx sales volumes and average net selling prices [3] - The label expansion of Cabometyx for treating pancreatic neuroendocrine tumors (pNET) and extra-pancreatic NET (epNET) is expected to contribute to incremental sales [5][6] Group 3: Drug Performance and Market Position - Cabometyx remains the leading TKI for advanced renal cell carcinoma (RCC) in both front-line and second-line treatment settings, with this trend expected to continue [4] - The FDA's recent approvals for Cabometyx are anticipated to drive additional revenue growth in Q2 [9] Group 4: Share Repurchase and Financial Strategy - The board has authorized a $500 million stock repurchase program, which is expected to enhance the bottom line as the ongoing repurchase program is completed [7] Group 5: Pipeline Developments - Positive results from the late-stage STELLAR-303 study for zanzalintinib, a third-generation oral TKI, are expected to add momentum to the pipeline ahead of earnings [8][9]

Core Insights - Moody's reported second-quarter 2025 adjusted earnings of $3.56 per share, exceeding the Zacks Consensus Estimate of $3.44, with an 8.5% year-over-year growth [1][7] - The company's revenues improved to $1.90 billion, surpassing the Zacks Consensus Estimate of $1.85 billion, reflecting a 4.5% increase year-over-year [3][7] - Operating expenses rose to $1.08 billion, up 3.6% year-over-year, impacting overall profitability [3][7] Financial Performance - Net income attributable to Moody's was $578 million or $3.21 per share, an increase from $552 million or $3.02 per share in the prior-year quarter [2] - Adjusted operating income reached $966 million, a 7.1% increase year-over-year, with an adjusted operating margin of 50.9%, up from 49.6% a year ago [3] Segment Performance - Moody's Investors Service (MIS) revenues slightly declined to $1.06 billion due to weakness in Corporate Finance and Financial Institutions, partially offset by growth in Structured Finance [4] - Moody's Analytics (MA) revenues increased by 10.5% year-over-year to $891 million, driven by strong demand for proprietary data and analytical insights [4] Balance Sheet and Liquidity - As of June 30, 2025, Moody's had total cash, cash equivalents, and short-term investments of $2.29 billion, down from $2.97 billion as of December 31, 2024 [5] - The company reported $7 billion in outstanding debt and $1.25 billion in additional borrowing capacity under its revolving credit facility [5] Share Repurchase Activity - In the quarter, Moody's repurchased 0.6 million shares at an average price of $460.76, with $0.9 billion of share repurchase authorization remaining [6] Guidance and Outlook - Moody's updated its 2025 guidance, expecting adjusted earnings of $13.50-$14.00 per share, revised from the previous target of $13.25-$14.00 [7][8] - The MIS segment's revenue growth is now expected to be in the low to mid-single-digit range, adjusted from stable to mid-single-digit growth [8] Strategic Developments - In June, Moody's fully acquired ICR Chile, enhancing its presence in Latin America's domestic credit markets, although the transaction is not expected to materially impact 2025 financial results [9][10]

Core Insights - Wabtec Corporation (WAB) is set to report its second-quarter 2025 results on July 24, with a history of positive earnings surprises, having outperformed the Zacks Consensus Estimate in three of the last four quarters, averaging a beat of 5.86% [1][4]. Earnings Performance - The Zacks Consensus Estimate for WAB's Q2 2025 earnings is $2.18 per share, reflecting a 0.46% upward revision in the past 60 days and an 11.22% increase from the previous year's actual [4][5]. - WAB's Q1 2025 earnings per share were reported at $2.28, exceeding the Zacks Consensus Estimate of $2.01, marking a 20.6% year-over-year improvement [10]. Revenue Estimates - The Zacks Consensus Estimate for WAB's Q2 2025 revenues is $2.77 billion, indicating a 4.84% growth from the previous year [5]. - Q2 2025 Freight revenues are estimated at $2.01 billion, representing a 4.6% increase year-over-year, while Transit revenues are pegged at $763 million, indicating a 5.4% growth [6][7]. Influencing Factors - The anticipated earnings performance is supported by higher sales and operating margin expansion, although supply chain issues, economic and political uncertainties, and high costs may pressure margins and revenues [4][8]. - Wabtec's operations outside the U.S. expose it to foreign currency exchange rate fluctuations, which is a significant concern for its financials [8]. Earnings Prediction Model - The current model predicts a potential earnings beat for Wabtec, supported by a positive Earnings ESP of +0.50% and a Zacks Rank of 2 (Buy) [9].

Core Viewpoint - West Pharmaceutical Services (WST) is expected to report second-quarter 2025 results on July 24, with prior performance indicating a strong earnings beat of 18.85% in the last quarter and an average surprise of 7.81% over the past four quarters [1] Q2 Estimates - The company anticipates second-quarter revenues between $720 million and $730 million, reflecting a 3% to 4% organic sales growth, with adjusted diluted earnings per share (EPS) projected at $1.50 to $1.55 [2][8] - The Zacks Consensus Estimate for revenues stands at $726 million, indicating a 3.4% growth year-over-year, while the consensus for earnings is $1.51 per share, showing a decline of 0.7% year-over-year [3] Revenue and Segment Performance - Total revenue is estimated at $722.2 million, representing a 3.2% organic improvement year-over-year, with the Proprietary Products segment expected to generate $583.5 million (4.6% organic growth) and Contract-Manufactured Products projected at $138.7 million [4] - The Proprietary Products segment is experiencing solid demand, particularly for high-value products like GLP-1-related components, which constituted over 73% of segment revenues in the first quarter [6] Segmental Analysis - Biologics within Proprietary Products is expected to show mixed but stable performance, with the SmartDose platform gaining traction, although early-quarter challenges may temper growth [7] - In Contract Manufacturing, growth in GLP-1 auto-injectors is offsetting declines from continuous glucose monitoring (CGM) products, with the Dublin facility expected to enhance drug-handling capabilities over time [9] Operational Insights - The company reported a solid first-quarter performance in 2025, with revenues of $698 million and EPS of $1.45, demonstrating resilience amid industry-wide destocking challenges [5] - Despite macro pressures and inventory dynamics, operational efficiencies and disciplined cost management are expected to support gross margins, although a softer mix of lower-margin products may weigh on performance [10] Earnings Prediction - The model predicts an earnings beat for WST, supported by a positive Earnings ESP of +0.57% and a Zacks Rank of 2 (Buy) [11][12]

Core Insights - Textron Inc. is set to release its second-quarter 2025 results on July 24, with an expected revenue growth of 2.9% year-over-year to $3.63 billion, despite anticipated earnings per share (EPS) decline of 5.8% to $1.45 [1][6][8] Group 1: Business Segment Performance - Textron Aviation is projected to see a revenue increase of 6% year-over-year, with estimates at $1,564 million [2] - The Bell unit is expected to report an 18% revenue growth year-over-year, with estimates at $936.8 million [3] - Textron Systems is likely to experience an 11.4% revenue decline year-over-year, with estimates at $286.3 million [4] - The Industrial segment is anticipated to see a 10.3% revenue decline year-over-year, with estimates at $819.4 million [5] Group 2: Financial Estimates and Backlog - The overall revenue performance is supported by strong sales in the Aviation and Bell units, while the Systems and Industrial segments face challenges [7] - Textron's backlog is projected to increase by 34.5% year-over-year to $18.05 billion [9] Group 3: Earnings Predictions - The company has a four-quarter average earnings surprise of 3.96%, and the current model indicates a potential earnings beat with an Earnings ESP of +0.23% [1][10] - Textron currently holds a Zacks Rank of 3, indicating a hold position [11]

Core Viewpoint - A. O. Smith Corporation (AOS) is expected to report second-quarter 2025 results on July 24, with mixed performance indicators suggesting potential challenges and opportunities ahead [1][9]. Revenue and Earnings Estimates - The Zacks Consensus Estimate for A. O. Smith's revenues is $987.3 million, reflecting a 3.6% decline from the previous year [2]. - The consensus estimate for adjusted earnings is 97 cents per share, indicating an 8.4% decline year-over-year [2]. Segment Performance - The North-American segment is anticipated to benefit from strong demand for commercial boilers and water treatment products, although a decline of 3.4% year-over-year to $764 million is expected due to softness in the residential and commercial water heater industry [3]. - The Rest of World segment is projected to generate revenues of $234 million, down 4.5% from the prior year, primarily due to challenges in the Chinese real estate market affecting residential water treatment and gas water heating products [4]. Cost and Acquisition Impact - A. O. Smith has faced high costs and expenses, with labor shortages and increased material costs negatively impacting performance, despite some moderation in supply-chain constraints [5]. - Recent acquisitions, such as the Pureit business from Unilever and Impact Water Products, are expected to positively influence the company's top line and enhance its position in the water treatment industry [6][7]. Earnings Expectations - A. O. Smith has an Earnings ESP of +4.48%, with the Most Accurate Estimate at $1.01 per share, suggesting a potential earnings beat despite the projected decline in EPS [8][9].

Core Insights - Tesla is expected to release its second-quarter 2025 results on July 23, focusing on improvements in its Energy & Service and Other Businesses [1] Financial Performance - In Q1 2025, Tesla reported earnings per share of 27 cents, down from 45 cents year-over-year, and missed the Zacks Consensus Estimate of 44 cents [3] - Total revenues for Q1 2025 were $19.33 billion, a 9% decline year-over-year, also missing the consensus mark of $21 billion [3] - Cash and cash equivalents stood at $37 billion as of March 31, 2025, with long-term debt decreasing to $5.3 billion from $5.7 billion at the end of 2024 [5] Energy & Service Business - Energy deployment in Q1 2025 rose to 10.4 GWh from 4.05 GWh in Q1 2024, with Energy Generation and Storage revenues totaling $2.73 billion, a 67% increase year-over-year [4] - The company expects revenues from the Energy Generation & Storage business to reach $3.04 billion, indicating a 0.7% year-over-year increase, with gross margin expected to rise to 26.7% from 24.6% [6] - Services and Other revenues are projected to be around $3.15 billion, reflecting a 20.7% year-over-year increase, with gross margin expected to improve to 10% from 6.4% [7] Market Expectations - The Zacks Consensus Estimate for Q2 2025 earnings is 40 cents per share, representing a 23.08% decline year-over-year, with sales estimated at $22.48 billion, an 11.85% decline [8] - Tesla's core EV business is facing challenges with weaker deliveries, but rising gross profits from Energy & Service and Other Businesses may offset losses in Q2 [8]

Core Insights - Fiserv, Inc. is set to release its second-quarter 2025 results on July 23, with a history of positive earnings surprises averaging 2.1% [2][7] Revenue Expectations - The Zacks Consensus Estimate anticipates revenues to increase by 8.5% year-over-year to $5.2 billion [3][10] - Merchant Solutions is expected to generate $2.8 billion in revenues, reflecting a 6.2% year-over-year growth, driven by Clover's growth and new partnerships [4][10] - Financial Solutions revenues are projected at $2.5 billion, indicating a 14.6% increase from the previous year, supported by product adoption and cross-platform advancements [5][10] - Processing and Services revenues are estimated at $4.5 billion, suggesting a 9.1% rise year-over-year, while Product segment revenues are expected to reach $1 billion, implying a 12.7% improvement [6][10] Earnings Predictions - The model predicts an earnings beat for Fiserv, with an Earnings ESP of +0.73% and a Zacks Rank of 2 (Buy) [7]